Biotechnology company developing therapies for hematological and musculoskeletal disorders.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing novel treatments for patients grappling with hematological and musculoskeletal disorders characterized by significant unmet medical needs. At the forefront of its pipeline is KER-050, a lead protein therapeutic designed to address low blood cell counts (cytopenias) prevalent in conditions like myelodysplastic syndromes and myelofibrosis. This innovative candidate holds promise for treating anemia and thrombocytopenia, currently undergoing clinical development.
In addition to its protein-based therapies, Keros Therapeutics is progressing KER-047, a small molecule compound intended for the treatment of anemia. This candidate is actively advancing through Phase 1 clinical trials, marking a significant step in addressing critical health challenges related to blood disorders.
Further bolstering its portfolio, the company is exploring KER-012, another small molecule in Phase 1 clinical trials. KER-012 targets conditions linked to bone loss such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension, underscoring Keros Therapeutics' commitment to expanding therapeutic options across multiple therapeutic areas.
Founded in 2015 and headquartered in Lexington, Massachusetts, Keros Therapeutics, Inc. combines cutting-edge research with a robust development strategy to propel its mission forward. The company's relentless pursuit of innovative treatments underscores its dedication to improving outcomes and quality of life for patients worldwide.